Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of ipilimumab alone or in combination with anti-PD-1 (IPI+PD1) in patients with metastatic melanoma resistant to PD1 monotherapy

Next Previous
Trial Profile

Safety and efficacy of ipilimumab alone or in combination with anti-PD-1 (IPI+PD1) in patients with metastatic melanoma resistant to PD1 monotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Programmed cell death-1 ligand-1 inhibitors
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 10 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top